시장보고서
상품코드
2150614

욕창 치료제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Bedsore Medicine Market Report: Trends, Forecast and Competitive Analysis to 2035

발행일: | 리서치사: 구분자 Lucintel | 페이지 정보: 영문 150 Pages | 배송안내 : 3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF, Excel & 1 Year Online Access (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,850 금액 안내 화살표 ₩ 6,495,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF & Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,700 금액 안내 화살표 ₩ 8,973,000
PDF, Excel & 1 Year Online Access (Corporate License) help
PDF & Excel 보고서를 동일 기업 내 동일 국가의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,850 금액 안내 화살표 ₩ 11,852,000
PDF, Excel & 1 Year Online Access (Global License) help
PDF & Excel 보고서를 동일 기업(완전 자회사 포함)의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 금액 안내 화살표 ₩ 13,393,000
※ 부가세 별도
한글목차
영문목차

욕창 치료제 시장

전 세계 욕창 치료제 시장의 전망은 밝으며, 병원, 진료소, 약국 및 온라인 시장에서 기회가 예상됩니다. 전 세계 욕창 치료제 시장은 2027년 19억 달러에서 2035년까지 약 21억 달러에 달할 것으로 예상되며, 2027-2035년까지 연평균 성장률(CAGR)은 2.9%를 기록할 전망입니다. 이 시장의 주요 성장 동인으로는 욕창 사례 수 증가, 상처 관리가 필요한 고령 인구 증가, 그리고 첨단 상처 피복재의 채택 확대 등이 꼽힙니다.

  • Lucintel사의 예측에 따르면 제품 유형별로는 드레싱이 사용 편의성과 상처 삼출액 누출 방지 기능 덕분에 예측 기간 중 높은 성장률을 보일 것으로 전망됩니다.
  • 용도별로는 온라인 약국 이용이 더욱 용이하고 편리해짐에 따라 예측 기간 중 ‘온라인’ 부문이 가장 높은 성장률을 보일 것으로 전망됩니다.
  • 지역별로는 E-Commerce의 성장과 의료 서비스 접근 환경의 변화로 인해 예측 기간 중 아시아태평양(APAC)이 가장 높은 성장률을 보일 것으로 예상됩니다.

욕창 치료제 시장의 새로운 동향

욕창 치료제 시장은 예측 기간(2025-2027년) 동안 조직의 치유와 재생을 동반한 예방 및 감염 관리 방향으로 발전할 것으로 예상됩니다. 고령 환자의 퇴원 및 욕창 예방 목표 수립에 따라 재택 상처 관리에 대한 관심이 높아지고 있습니다. 보험 급여 제한 및 제3자 관리 기관에 의한 비정상적으로 높은 지급액에 대한 심사가 강화되면서 구매 패턴에 영향을 미치고 있습니다. 당사의 보고서에 따르면 임상적으로 유효하고 투여 부담을 줄이며 치료 총비용을 절감할 수 있는 제품에 대한 수요가 증가하고 있습니다.

  • 지속가능성: 첨단 상처 관리 제품에서 염소계 용제 및 재활용 불가능한 성분의 사용을 줄이기 위한 노력은 앞으로도 지속될 전망입니다. 헬스케어 부문 구매 담당자들이 첨단 상처 관리 제품의 환경 부하 저감을 더욱 중시하는 경향은 생태 발자국 감소를 목표로 할 것입니다.
  • 고급 상처 관리 제품: 수분 균형이 뛰어나고 착용 시간이 긴 제품의 인기는 앞으로도 계속 높아질 것입니다. 유럽의 욕창 예방 및 치료 지침의 차기 개정은 향후 3-5년 이내에 예정되어 있으며, 제품 선호도에 영향을 미칠 가능성이 있습니다.
  • 디지털 상처 관리: 재택 간호 및 병원 간호에서 상처 기록 및 측정을 위한 디지털 및 전자 기록의 도입은 향후 5-10년 동안 계속해서 증가할 것입니다. 당뇨병 유병률의 증가에 따라 디지털 및 원격 상처 관리 모니터링에 대한 수요가 높아질 전망입니다.
  • 재택 간호: 임상 현장 이외에서 이루어지는 치료(즉, 원격의료, 방문 진료, 이동형 간호팀 등)는 특히 고령층을 중심으로 확대되고 있습니다. 세계보건기구(WHO)의 추산에 따르면 2030년에는 60세 이상 고령자가 14억 명에 달할 것으로 예상됩니다. 편의성이 높은 제품 설계와 쉽게 따를 수 있는 사용 절차가 제품 개발을 주도하며 시장 침투율을 높여갈 것입니다.
  • 재생의학: 기존의 상처 관리 및 조직 복원 제품을 대체할 대안 요법이 잇달아 등장하고 있습니다. 음압 상처 치료(NPWT)와 치료용 성장인자 전달 시스템이 주목받고 있습니다. 일부 생물제제는 만성 상처나 치유가 어려운 상처의 관리에 대해 최근 FDA 승인을 획득했습니다. 향후 5년 동안, 특히 그 유효성이 입증되고 보험사의 급여가 승인된다면, 더 많은 생물제제가 시장에서 주목을 받을 가능성이 있습니다.

시장에서는 만성질환 예방 및 병원 밖 치료를 촉진하는 제품에 대한 뚜렷한 추세가 관찰됩니다. 이러한 추세에 부합하는 제품의 차별화는 적절한 시장 점유율 회복과 유지에 도움이 될 것입니다. 통합적인 치유 성과를 보여주지 못하는 제품은 상품화라는 운명을 맞이하게 될 것입니다. 공개 시장은 계속해서 가격 책정의 제약 요인으로 작용할 것입니다. 제조사와 통합자(즉, 임상의 및 유통업체) 간의 장기적인 파트너십은 지속가능한 제품과 플랫폼의 번영에 기여할 것입니다.

욕창 치료제 시장의 최근 동향

욕창 치료제 제품 개발은 첨단 상처 관리 및 외상 관리에 통합된 생물제제나 스마트 제품에 초점이 맞춰질 것으로 예상됩니다. 특히 고령자, 장기 요양 시설 및 지역사회에서 보험 급여 정책이 제품 채택에 큰 영향을 미칠 것으로 예상됩니다.

  • 욕창 및 상처 치료용 생물제제: 많은 공급업체들이 욕창 및 상처 치료를 위한 첨단 조직공학 제품 및 관련 제품을 개발하고 있습니다. 2025년 CMS(미국 의료보험서비스센터) 규정에 따라 특정 피부·조직 대체재에 대한 지급이 표준화될 것으로 예상되며, 이로 인해 공급업체 간의 가격 경쟁이 촉진되고 임상적 및 경제적 성과를 입증해야 할 필요가 생길 것입니다.
  • 첨단 상처 치료: 각 기업은 상처 치료를 위한 첨단 기술을 활용한 제품을 시장에 출시하고 있습니다. 주요 제조사들은 제품 혁신에 투자하고 있으며, 예를 들어 스미스 앤 네퓨(Smith & Nephew)는 2024년 상처 치료 및 하지·발, 기타 정형외과용 지지대·보조기 제품의 매출이 60억 달러에 달했다고 보고했습니다. 각 기업은 총비용 및 기타 가치 기반 성과를 기준으로 첨단 기술을 활용한 제품으로 차별화를 꾀할 것입니다.
  • 예방 및 임상 데이터를 위한 파트너십: 공급업체들은 임상 데이터를 수집하기 위해 첨단 욕창 예방용 매트리스 및 기타 제품을 전자 건강 기록(EHR)과 연동하고 있습니다. 2025년 NHS IP(통합 의료 계획)에 따라 트러스트는 욕창 및 기타 부상 예방을 우선시할 수 있게 되었습니다. 이에 따라 임상 데이터와 소프트웨어를 통합하여 예방 및 건강 증진 베스트 프랙티스를 자동화하는 첨단 제품에 대한 관심이 높아지고 있습니다.
  • 상처 관리 분야의 공급업체 확대: 미국 인구조사국의 예측에 따르면 2025년까지 65세 이상 인구는 7,150만 명에 달할 것으로 예상됩니다. 이에 따라 지역사회에서 병원으로의 치료 전환은 앞으로도 계속될 것입니다. 인구 통계학적 변화로 인해 대면 접촉을 최소화하거나 아예 하지 않는 형태로 제공되는 원격 치료에 대한 수요가 증가할 것입니다. 또한 이러한 치료는 의료 전문가가 아닌 다른 사람에 의해 제공될 가능성도 있습니다.
  • 조달 동향의 변화: 미국의 의료제도 초점은 점차 가치 기반 지불 방식으로 전환되고 있습니다. 병원에서는 의료기기 조달 관리 방식에 변화가 일어나고 있습니다. 이러한 변화의 초점은 특정 의료기기가 투자 비용을 회수하는 데 걸리는 기간, 해당 기기의 감염 위험, 그리고 특정 상처가 치유되는 데 걸리는 기간에 있습니다. FDA는 2025년까지 수많은 상처 관리 기술을 심사할 것으로 예상됩니다.

상처 치유 생명공학의 목표는 조직의 복구와 재형성입니다. 가장 유망한 상업적 기회는 상처 합병증 예방 관리와 디지털 기술을 활용한 치료에 있습니다. 상처의 특성에 따라 치료는 지역사회 또는 병원에서 이루어질 수 있습니다. 증거 기반이 탄탄하고 해당 기술을 판매할 수 있는 시장이 많을수록 제품 비용을 회수할 가능성은 높아집니다.

목차

제1장 개요

제2장 시장 개요

제3장 시장 동향과 예측 분석

제4장 세계의 욕창 치료제 시장 : 유형별

제5장 세계의 욕창 치료제 시장 : 용도별

제6장 지역별 분석

제7장 북미의 욕창 치료제 시장

제8장 유럽의 욕창 치료제 시장

제9장 아시아태평양의 욕창 치료제 시장

제10장 RoW의 욕창 치료제 시장

제11장 경쟁 분석

제12장 기회와 전략 분석

제13장 밸류체인 전체에서 주요 기업의 기업 개요

제14장 부록

KSA 26.10.22

Bedsore Medicine Market

The future of the global bedsore medicine market looks promising with opportunities in the hospital, clinic, pharmacy, and online markets. The global bedsore medicine market is expected to reach an estimated $2.1 billion by 2035 from $1.9 billion in 2027 with a CAGR of 2.9% from 2027 to 2035. The major drivers for this market are the increasing incidence of pressure ulcer cases, the rising geriatric population requiring wound care, and the growing adoption of advanced wound dressings.

  • Lucintel forecasts that, within the type category, dressing is expected to witness higher growth over the forecast period due to dressing ease of use and protection against leakage of wound fluid.
  • Within the application category, online is expected to witness the highest growth over the forecast period due to increased ease and convenience of online pharmacy.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growth of e-Commerce and changes in the accessibility of Healthcare services.

Emerging Trends in Bedsore Medicine Market

Bedsore medicine market is expected to advance toward prevention and infection control with tissue healing and regeneration during the forecast period (2025-2027). Discharge of elderly patients and pressure injury prevention targets has increased focus on home based wound care. Limited reimbursement and increasing scrutiny on out-lier payments by third party administrators has affected buying patterns. Our report suggests that demand is for products which are clinically effective and ease the burden of administration and reduce total cost of treatment.

  • Sustainability: Continued efforts to decrease the use of chlorinated solvents and non-recyclable components in advanced wound care products will continue. Increased emphasis on footprint reductions in advanced wound care products by buyers in the Healthcare sector will be aimed at reducing the ecological footprint.
  • Advanced Wound Care Products: The use of products with moisture balance, and extended wear time will continue to gain in popularity. The next update of pressure ulcer prevention and treatment guidelines in Europe is expected in the next 3-5 years and may influence product preferences.
  • Digital Wound Care: The adoption of digital and electronic records for documenting and measuring wounds in home and hospital based care will continue to increase in the next 5 to 10 years. The increasing prevalence of diabetes will create an increased demand for digital and remote wound care monitoring.
  • Home-based Care: Treatment provided outside of a clinical setting (i.e. telehealth, home visits, mobile Care teams, etc.) is growing, especially among the elderly. In 2030, the WHO estimates there will be 1.4 billion people aged 60 and above. Convenient product design and simple-to-follow product use protocols will lead product development and increase market penetration.
  • Regenerative Medicine: Alternative therapies to traditional wound care and tissue-repair products continue to emerge. Negative pressure Wound Therapy (NPWT) is gaining traction as are delivery systems for therapeutic growth factors. Some biologic products have recently received FDA approval for the management of chronic and hard-to-heal wounds. Additional biologic products may gain traction in the marketplace in the next five years, especially if they are proven to be effective and reimbursed by payers.

There are clear trends in the marketplace toward products that help prevent chronic conditions and promote care outside of the hospital. Product differentiation along these lines will help recover and defend adequate market share. Commoditization will be the market fate for products that lack integrated healing outcomes. The public market will continue to dictate pricing constraints. Long-term partnerships between manufacturers and integrators (i.e., clinicians, distributors) will help durable products and platforms thrive.

Recent Developments in the Bedsore Medicine Market

Product development of bedsore medication is expected to focus on biologics and smart products integrated in advanced wound care and trauma management. Expect a strong influence of reimbursement policies on adoption, especially for the elderly, in long term care and in the community.

  • Biologics for Pressure Injuries and Wounds: A number of suppliers are developing advanced tissue-engineered products for pressure injuries and wounds and related products. The 2025 CMS rules are expected to standardize payments for certain skin and tissue substitutes, thus fostering price competition for suppliers to demonstrate clinical and economic outcomes.
  • Advanced Wound Care: Suppliers are launching advanced, technology-enabled products for wound care. Leading suppliers are investing in product innovation, e.g. Smith & Nephew reported 2024 wound care and leg, foot and other orthopedic supports and braces product revenue of $6 billion. Suppliers will differentiate advanced, technology-enabled products based on total cost and other value-based outcomes.
  • Partnerships for Prevention and Clinical Data: Suppliers are integrating advanced pressure-relieving surfaces and other products with EHRs to capture clinical data. The 2025 NHS IP allows trusts to prioritize prevention of pressure injuries, and other injuries. Thus, there is increased focus on advanced products that integrates clinical data and software to automate best practice prevention and health promotion.
  • Wound Supplier Expansion: The U.S. Census expects the over 65 population to reach 71.5 million by 2025. As this happens, the withdrawal of care from the community to the hospital will continue. The shifting demographics will increase the need for outlying care, which will be delivered using less (or no) face-to-face interaction. Further, the care may be provided by a non-healthcare professional.
  • Purchasing Shifts: The focus of the U.S. healthcare system is gradually changing to value-based payment. In hospitals, shifts are occurring in how the purchase of devices is managed. The focus of the shifts is on the length of time a given device will take to pay for itself and on the infectious nature of the device and how long it takes for a given wound to heal. The FDA is expected to review a number of wound-management technologies by 2025.

The goal of wound-healing biotechnology is the repair and remodeling of tissues. The best commercial opportunities are in the preventative care of wound complications, and digitally-assisted care. Depending on the nature of the wound, the care may be provided in the community or in the hospital. The better the evidence, and the more places the technology is available for sale, the better the opportunities to recover the cost of the product.

Strategic Growth Opportunities in the Bedsore Medicine Market

Bedsore medicine is moving beyond simple topical treatments and focus is shifting toward prevention and healing. Population aging, reimbursement policies of hospitals, proper home health care, and improved diagnosis will increase the market from 2024 to 2026. According to Lucintel, there are ample opportunities in this field where substantial clinical evidence, reimbursement policies, and ease of use of a product merge.

  • Use of Advanced Biologics: In the field of wound care, advancement has been primarily in the use of different growth factors, cellular matrix and other combination therapies. As of March, 2025, the FDA had wound product codes for 20 or more cellular and tissue based products. Clinical evidence and usability of a product will be the primary factor for pricing and reimbursement in the field of wound care in the next 5 years.
  • Pressure Injury Prevention and Treatment: There has been significant improvement in the materials used for wound care and treatment. Negative pressure wound therapy and other telehealth and remote monitoring systems will allow treatment and prevention of pressure injuries to be shifted from hospitals to the home. Payments made to hospitals by CMS under the Hospital Acquired Condition Reduction Program will help fund research to develop new products.
  • Digital Wound Monitoring: Imaging software and connected mattresses, in conjunction with risk-assessment tools, have the potential to create new sources of revenue from drugs. In April 2025, the FDA's database indicated that over 700 wound-care-related medical devices had been cleared. Objective software to monitor healing may promote the proactive management of wounds, improve the code director's assessment of wound healing, and facilitate the adoption of more appropriate and valuable wound healing interventions.
  • Long-term Care: The use of lower-complexity products, in conjunction with standardized processes, in nursing homes and rehabilitation centers has the potential to be profitable. In February 2025, the CMS reported that over 1.2 million people resided in Medicare-participating nursing homes. Companies that develop products or solutions to address the staffing challenges in these facilities are likely to be successful and may gain lasting business in the short-term.
  • Biomaterials: The use of polymeric systems, packaging systems, and wound dressings that integrate principles of design for sustainability may improve the competitiveness of wound care products. The EU's Packaging and Packaging Waste Directive will likely come into effect for Member States in August 2026. The authorization of these directives may improve the position of certain suppliers to gain access to the procurement of healthcare services.

The largest opportunities will come from products that decrease the time spent by the caregiver to accomplish other tasks while demonstrating clinical evidence of wound healing. Early integration of reimbursement and clinical teams will facilitate the creation of products that achieve the greatest clinical impact. The international business will be pursued; however, the quality of the company's distribution channels and education of the local healthcare professionals will influence the company's success

Bedsore Medicine Market Drivers and Challenges

Retain the content's layout (i.e. bullet points, spacing, Headings, etc.) as closely as possible. Do not alter the companies cited in the content. Lucintel and other similar names must be correctly spelled. These sentences will not be included in the final copy.

Growing and aging populations create more demand for bedsore treatment medications. Lucintel mentions that the focus on patient care and the encouragement of innovation will stimulate the bedsore treatment medication market.

The factors responsible for driving this market include :

  • Aging Population: It is predicted that by the year 2030, the global population aged 60 years and above will be 1.4 billion. The increase in elderly people will increase the at risk population for pressure ulcers and other injuries. Long term policies of various nations will ensure continuous increase in the demand for products and services to prevent pressure sores.
  • Technology: Antimicrobial agents and advanced biomaterials have improved the management of wounds. Similar developments are occurring in the areas of smart dressings, digital monitoring and oxygen therapy. Sensor-based technologies that alert to the presence of decubitus ulcers and other wounds are becoming available and may stimulate the development of new treatments. The use of data to drive decisions in medicine will promote the use of advanced treatments for pressure ulcers in both hospitals and home care.
  • Growth in Health Care Spending: Increased spending on health care will allow facilities to purchase more advanced wound care products and technologies. It is expected that health care spending will increase due to the rise of chronic health conditions. In the medium-term, the improved ability and will of health care systems in the poorer nations to fund wound care services will drive the growth of the market.
  • Improved Standards: Various initiatives of national and international health care agencies to improve the quality of care and reduce health care associated conditions fostered improvements in prevention and treatment of pressure ulcers. Standardization of methods and procedures has allowed for a better clinical framework. In the 2025-2029 time frame, it is expected that greater demands for quality in health care will create a greater demand for improved bedsore management technologies.
  • Product Innovation: New antimicrobial gels and ointments, collagen-based products, and hydrocolloid dressings are examples of products targeting the first stages of wound healing. Negative pressure wound therapy and combination products focus on the later stages. Innovation helps clinicians manage individual cases and minimize complications. In the short term, the bedsore medicine market will benefit from the increased competition from products derived from recent advances in technology.

The challenges facing this market include:

  • High Treatment Costs: The use of sophisticated products and extended duration of care increases financial burden on the healthcare system and delays wound healing. In May 2025, health personnel mentioned financial and staffing resources constraints. During the next three to five years, the high degree of income and product price dependency will result in restricted access in low and middle income countries. Inadequate and slow reimbursement policies will further limit the use of bedsore medicine in developing countries.
  • Complex Clinical Management: The presence of complications, such as pressure sores, usually leads to the use of other products and services (e.g., dietary and physical therapy, infection control products, and aids to assist ambulation). In July 2025, the use of integrated and multidisciplinary medicine and teams was also cited. Noncompliance with clinical guidelines and poor adherence to treatment increases the duration of the healing process and the risk of complication. The variation in the clinical condition and the degree of adherence to treatment in the general population will result in unstable and unpredictable demand for bedsore medicine.
  • Access Gaps: Non-uniform insurance, rural healthcare, and varying drug approvals can restrict patients' access to innovative therapies. As of September 2025, the majority of healthcare systems hadn't changed their policies for funding innovative therapies; however, many limited reimbursement for advanced wound care. These access gaps can hinders the market growth and investment for innovative therapies. In the next 3 to 5 years, various therapies will be developed with better reimbursement potential and more convenient means of distribution.

Changes within the bedsore treatment market will be influenced by long-term trends including increased public and private investment in healthcare, economic growth, advances in medical technology, and greater regulation of the medical industry. Together, these will likely improve diagnosis, treatment, and monitoring of patients. The cost and complexity of treatment may continue to limit the adoption of medical innovations. The most successful companies will be able to integrate multiple elements of a given market including affordability, performance, and distribution. The most successful companies will also integrate collaborations with various industry stakeholders to enhance integration of innovative medical devices.

List of Bedsore Medicine Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies bedsore medicine market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bedsore medicine market companies profiled in this report include-

  • Nipro
  • Chongqing Kerui Pharmaceutical
  • Smith & Nephew
  • Convatec
  • B Braun Melsungen

Bedsore Medicine Market by Segment

The study includes a forecast for the global bedsore medicine market by type, application, and region.

Bedsore Medicine Market by Type [Value ($B) from 2019 to 2035]:

  • Dressing
  • Antibiotic Ointment

Bedsore Medicine Market by Application [Value ($B) from 2019 to 2035]:

  • Hospital
  • Clinic
  • Pharmacy
  • Online

Bedsore Medicine Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Bedsore Medicine Market

Advanced wound dressings combined with digital and other forms of monitoring are expected to play an increasing role in the prevention and management of pressure injuries. From 2025 to 2027 the implementation of new reimbursement policies and the hospital Acute Care Act, together with new investments in the production of medical devices, will influence procurement. The Lucintel report published in 2022 indicated the above mentioned policies and programs would enhance the market's interest in evidence based products.

  • USA: The Centers for Medicare and Medicaid Services (CMS) have included the prevention of pressure ulcers in their Hospital Acquired Condition reduction program, which means participating hospitals would face a 1% reduction in their reimbursement for the program period (from October 2025 to September 2028). This would encourage the purchase of pressure ulcer prevention products and services by hospitals for the program period.
  • China: In 2025 the Chinese medical device regulatory agency (NMRA) continued its program of prioritized reviews for innovative medical devices. At the same time several Chinese companies expanded their portfolio of advanced wound-healing products. As a result, several suppliers of wound care products reported a double-digit growth in their China sales (December 2025).
  • Germany: German manufacturers of wound care products have further adapted their offerings in the German market in response to the requirements of the EU MDR. Transition periods for Class III medical devices end on December 31, 2027. The European Commission recently approved a request from industry to extend these deadlines. Bed sore prevention and treatment products will only be available at German hospitals for which the market has remained open for the bedsore prevention and treatment products.
  • India: The digital health records initiative Ayushman Bharat has crossed 750 million health records. This initiative has the potential to improve the documentation of chronic wounds and pressures injuries. Improved documentation has the potential to improve integrated and continuous wound care. Increased transparency has the potential to enhance the procurement of wound care products.
  • Japan: The home care policy of Japan's Ministry of Health, Labor and Welfare has promoted the development of easy-to-use bedsore products. These products are expected to have a positive impact on the pressure injury prevention outside of acute care facilities.

Features of the Global Bedsore Medicine Market

  • Market Size Estimates: bedsore medicine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: bedsore medicine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: bedsore medicine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the bedsore medicine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bedsore medicine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the bedsore medicine market by type (dressing and antibiotic ointment), application (hospital, clinic, pharmacy, and online), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Bedsore Medicine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Dressing : Trends and Forecast 2019 to 2035
  • 4.4 Antibiotic Ointment : Trends and Forecast 2019 to 2035

5. Global Bedsore Medicine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Hospital : Trends and Forecast 2019 to 2035
  • 5.4 Clinic : Trends and Forecast 2019 to 2035
  • 5.5 Pharmacy : Trends and Forecast 2019 to 2035
  • 5.6 Online : Trends and Forecast 2019 to 2035

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Bedsore Medicine Market by Region

7. North American Bedsore Medicine Market

  • 7.1 Overview
  • 7.2 North American Bedsore Medicine Market by Type
  • 7.3 North American Bedsore Medicine Market by Application
  • 7.4 The United States Bedsore Medicine Market
  • 7.5 Canadian Bedsore Medicine Market
  • 7.6 Mexican Bedsore Medicine Market

8. European Bedsore Medicine Market

  • 8.1 Overview
  • 8.2 European Bedsore Medicine Market by Type
  • 8.3 European Bedsore Medicine Market by Application
  • 8.4 German Bedsore Medicine Market
  • 8.5 French Bedsore Medicine Market
  • 8.6 Italian Bedsore Medicine Market
  • 8.7 Spanish Bedsore Medicine Market
  • 8.8 The United Kingdom Bedsore Medicine Market

9. APAC Bedsore Medicine Market

  • 9.1 Overview
  • 9.2 APAC Bedsore Medicine Market by Type
  • 9.3 APAC Bedsore Medicine Market by Application
  • 9.4 Chinese Bedsore Medicine Market
  • 9.5 Indian Bedsore Medicine Market
  • 9.6 Japanese Bedsore Medicine Market
  • 9.7 South Korean Bedsore Medicine Market
  • 9.8 Indonesian Bedsore Medicine Market

10. ROW Bedsore Medicine Market

  • 10.1 Overview
  • 10.2 ROW Bedsore Medicine Market by Type
  • 10.3 ROW Bedsore Medicine Market by Application
  • 10.4 Middle Eastern Bedsore Medicine Market
  • 10.5 South American Bedsore Medicine Market
  • 10.6 African Bedsore Medicine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Bedsore Medicine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Nipro
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Chongqing Kerui Pharmaceutical
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Smith & Nephew
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Convatec
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 B Braun Melsungen
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Kaken Pharmaceutical
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Tayca Pharmaceutical
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Meiji Holdings
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 Ono Pharmaceutical
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Sun Pharma
    • Company Overview
    • Bedsore Medicine Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기